Health Care [ 3/12 ] | Life Sciences Tools & Services [ 29/74 ]
NASDAQ | Common Stock
Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific.
Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.
The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample.
It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis.
In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives.
Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients.
The company was incorporated in 2011 and is headquartered in Fremont, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 6, 24 | -0.64 Decreased by -33.33% | -0.35 Decreased by -82.86% |
| Aug 7, 24 | -0.24 Increased by +52.00% | -0.37 Increased by +35.14% |
| May 8, 24 | -0.26 Increased by +57.38% | -0.41 Increased by +36.59% |
| Feb 28, 24 | -0.54 Increased by +19.40% | -0.50 Decreased by -8.00% |
| Nov 7, 23 | -0.48 Increased by +17.24% | -0.53 Increased by +9.43% |
| Aug 8, 23 | -0.50 Increased by +16.67% | -0.53 Increased by +5.66% |
| May 3, 23 | -0.61 Increased by +3.17% | -0.58 Decreased by -5.17% |
| Feb 23, 23 | -0.67 Decreased by -48.89% | -0.64 Decreased by -4.69% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 25.71 M Increased by +40.89% | -39.09 M Decreased by -34.34% | Decreased by -152.04% Increased by +4.66% |
| Jun 30, 24 | 22.58 M Increased by +35.22% | -12.80 M Increased by +46.56% | Decreased by -56.70% Increased by +60.48% |
| Mar 31, 24 | 19.52 M Increased by +3.53% | -12.97 M Increased by +54.75% | Decreased by -66.42% Increased by +56.29% |
| Dec 31, 23 | 19.68 M Increased by +17.66% | -26.58 M Increased by +14.43% | Decreased by -135.12% Increased by +27.28% |
| Sep 30, 23 | 18.25 M Increased by +22.81% | -29.10 M Decreased by -9.84% | Decreased by -159.47% Increased by +10.56% |
| Jun 30, 23 | 16.70 M Decreased by -8.45% | -23.95 M Increased by +13.04% | Decreased by -143.45% Increased by +5.01% |
| Mar 31, 23 | 18.86 M Increased by +23.86% | -28.66 M Decreased by -1.60% | Decreased by -151.96% Increased by +17.98% |
| Dec 31, 22 | 16.72 M Decreased by -19.15% | -31.07 M Decreased by -53.81% | Decreased by -185.79% Decreased by -90.23% |